Author:
Burmester Gerd R,Rubbert-Roth Andrea,Cantagrel Alain,Hall Stephen,Leszczynski Piotr,Feldman Daniel,Rangaraj Madura J,Roane Georgia,Ludivico Charles,Lu Peng,Rowell Lucy,Bao Min,Mysler Eduardo F
Subject
General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology
Reference10 articles.
1. Biologics-based therapy for the treatment of rheumatoid arthritis;Scott;Clin Pharmacol Ther,2012
2. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate;Maini;Arthritis Rheum,2006
3. Optimal dose prediction by pharmacokinetic and biomarker response of subcutaneous tocilizumab treatment a Phase I/II study evaluating the safety, pharmacokinetics and clinical response in patients with rheumatoid arthritis;Ohta;Arthritis Rheum,2010
4. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing;Stubenrauch;Clin Ther,2010
5. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial;Smolen;Lancet,2008
Cited by
216 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献